DNAtrix Gets $20M For Cancer Killing Viruses

San Diego-based DNAtrix, which is developing modified viruses intended to treat aggressive cancers, has raised $20M in a Series B financing. The funding was led by Morningside Ventures, and also included Mercury Fund, Targeted Technology Fund and others. DNAtrix say sit is modifying a common cold virus so that it specifically targets and kills cancer cells. The company's lead product, DNX-2401, is in late stage clinical trials. As part of the funding, Reenie McCarthy of Morningside joins the company's board. More information »